Show simple item record

dc.contributor.authorCastilla, Jesús
dc.contributor.authorNavascués, Ana
dc.contributor.authorCasado, Itziar
dc.contributor.authorDíaz-González, Jorge
dc.contributor.authorPérez-García, Alejandra
dc.contributor.authorFernandino, Leticia
dc.contributor.authorMartínez-Baz, Iván
dc.contributor.authorAguinaga, Aitziber
dc.contributor.authorPozo Sánchez, Francisco 
dc.contributor.authorEzpeleta, Carmen
dc.date.accessioned2019-06-04T11:24:00Z
dc.date.available2019-06-04T11:24:00Z
dc.date.issued2017-02
dc.identifier.citationEuro Surveill. 2017 Feb;22(7).es_ES
dc.identifier.issn1025-496Xes_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/7723
dc.description.abstractThe 2016/17 mid-season vaccine effectiveness estimate against influenza A(H3N2) was 15% (95% confidence interval: -11 to 35) in Navarre. Comparing to individuals unvaccinated in the current and four prior seasons, effectiveness was 24% for current and 3-4 prior doses, 61% for current and 1-2 prior doses, 42% for only current vaccination, and 58% for 3-4 prior doses. This suggests moderate effectiveness for different combinations of vaccination in the current and prior seasons.es_ES
dc.description.sponsorshipThis study was supported by the Horizon 2020 program of the European Commission (agreement 634446); by the I-MOVE (Influenza Monitoring Vaccine Effectiveness in Europe) Network funded by the European Centre for Disease Prevention and Control; by La Caixa Foundation; and by the Carlos III Institute of Health with the European Regional Development Fund (ERDF) (CM15/00119, INT15/00182).es_ES
dc.language.isoenges_ES
dc.publisherEuropean Centre for Disease Prevention and Controles_ES
dc.relation.isversionofPublisher's versiones_ES
dc.rights.urihttp://creativecommons.org/licenses/by-nc-sa/4.0/*
dc.subjectcase control studyes_ES
dc.subjectinfluenzaes_ES
dc.subjectinfluenza vaccinees_ES
dc.subjectinfluenza-like illnesses_ES
dc.subjectrepeated vaccinationes_ES
dc.subjectvaccine effectivenesses_ES
dc.subject.meshAdolescent es_ES
dc.subject.meshAdult es_ES
dc.subject.meshAged es_ES
dc.subject.meshChild es_ES
dc.subject.meshHumans es_ES
dc.subject.meshInfluenza A Virus, H3N2 Subtype es_ES
dc.subject.meshInfluenza Vaccines es_ES
dc.subject.meshVaccination es_ES
dc.subject.meshYoung Adult es_ES
dc.titleCombined effectiveness of prior and current season influenza vaccination in northern Spain: 2016/17 mid-season analysises_ES
dc.typeArtículoes_ES
dc.rights.licenseAtribución-NoComercial-CompartirIgual 4.0 Internacional*
dc.identifier.pubmedID28230523es_ES
dc.format.volume22es_ES
dc.format.number7es_ES
dc.identifier.doi10.2807/1560-7917.ES.2017.22.7.30465es_ES
dc.contributor.funderLa Caixa Foundation
dc.contributor.funderEuropean Regional Development Fund (ERDF)
dc.description.peerreviewedes_ES
dc.identifier.e-issn1560-7917es_ES
dc.relation.publisherversionhttps://doi.org/10.2807/1560-7917.ES.2017.22.7.30465es_ES
dc.identifier.journalEurosurveillancees_ES
dc.repisalud.centroISCIII::Centro Nacional de Microbiologíaes_ES
dc.repisalud.institucionISCIIIes_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/EC/H2020/634446es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/CM15/00119es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/INT15/00182es_ES
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses_ES


Files in this item

Acceso Abierto
Thumbnail

This item appears in the following Collection(s)

Show simple item record

Atribución-NoComercial-CompartirIgual 4.0 Internacional
This item is licensed under a: Atribución-NoComercial-CompartirIgual 4.0 Internacional